Growth and luteinizing hormone decreases during nafenoic acid therapy.
D000284:Administration, Oral; D000328:Adult; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D003920:Diabetes Mellitus / Q000188:drug therapy; D005640:Follicle Stimulating Hormone / Q000097:blood; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010636:Phenols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011422:Propionates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013737:Testis / Q000187:drug effects; D013960:Thyroid Function Tests; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D007328:Insulin; D009281:Naphthalenes; D010636:Phenols; D011422:Propionates; D014280:Triglycerides; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D002784:Cholesterol; D003404:Creatinine